Key result
Patients with heart failure and diabetes were more often treated with diuretics (64% vs 42%, p<0.001) and beta blockers (88% vs 83%, p<0.001) compared to those without diabetes.
Why the study?
The study aimed to investigate the prevalence of known diabetes, undiagnosed diabetes, and pre-diabetes in real-world HF, and whether HF or diabetes treatments differ by glycaemic status or HF phenotype.
Cross-Sectional (n=2,326)
No
Absolute Event Rate: 64% vs 42%
p-value: p=<0.001
Diabetes and pre-diabetes are highly prevalent in real-world heart failure patients, affecting half of the population, and their presence is associated with higher use of diuretics and beta-blockers.
AIMS: The aim of this study was to investigate a real-world heart failure (HF) cohort regarding (1) prevalence of known diabetes mellitus (DM), undiagnosed DM and pre-diabetes, (2) if hf treatment differs depending on glycaemic status and (3) if treatment of DM differs depending on HF phenotype. METHODS: All patients who had received a diagnosis of HF at Umeå University Hospital between 2010 and 2019 were identified and data were extracted from patient files according to a prespecified protocol containing parameters for clinical characteristics, including echocardiogram results, comorbidities, fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) values. Patients' HF phenotype was determined using the latest available echocardiogram. The number of patients with previous DM diagnosis was assessed. Patients without a previous diagnosis of DM were classified as non-DM, pre-diabetes or probable DM according to FPG and HbA1c levels using WHO criteria. RESULTS: In total, 2326 patients (59% male, mean age 76±13 years) with HF and at least one echocardiogram were assessed. Of these, 617 (27%) patients had a previous diagnosis of DM. Of the 1709 patients without a previous diagnosis of DM, 1092 (67%) patients had either an FPG or HbA1c recorded, of which 441 (41%) met criteria for pre-diabetes and 97 (9%) met criteria for probable diabetes, corresponding to 19% and 4% of the entire cohort, respectively. Patients with HF and diabetes were more often treated with diuretics and beta blockers compared with non-DM patients (64% vs 42%, p<0.001 and 88% vs 83%, p<0.001, respectively). There was no difference in DM treatment between HF phenotypes. CONCLUSIONS: DM and pre-diabetes are common in this HF population with 50% of patients having either known DM, probable DM or pre-diabetes. Patients with HF and DM are more often treated with common HF medications. HF phenotype did not affect choice of DM therapy.
No takes yet. Share an insight, caveat, or question.
Håkansson et al. (2022) conducted a cross-sectional in Heart failure (n=2,326). Diabetes mellitus vs. Non-diabetes mellitus was evaluated on Treatment with diuretics (p=<0.001). Patients with heart failure and diabetes were more often treated with diuretics (64% vs 42%, p<0.001) and beta blockers (88% vs 83%, p<0.001) compared to those without diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: